IDEXX chief financial officer to retire in June, successor named
Photo / Courtesy, IDEXX Laboratories Inc.
CFO Brian McKeon, left, plans to retire from IDEXX on June 1, 2025. He will be succeeded as CFO by Andrew Emerson, starting March 1, 2025.
After more than 20 years with IDEXX Laboratories Inc. (Nasdaq: IDXX) and a decade as chief financial officer, Brian McKeon plans to retire from the company, effective June 1, 2025.
He will be succeeded by Andrew Emerson, who currently serves as senior vice president of finance for corporate and for the company's companion animal group division. Emerson will start his new role on March 1, 2025.
During the three-month transition period, McKeon will serve as executive vice president and special advisor to the company, the Westbrook-based provider of veterinary diagnostics and software said in Thursday's announcement.
"Andrew brings nearly 20 years of broad financial experience to his new role, as well as nine years of deep and intimate knowledge of our strategy and finances, working side by side with Brian, making him a natural fit to succeed Brian as CFO,” said IDEXX President and CEO Jay Mazelsky.
“We are confident Andrew is the right person to help drive our next phase of growth and profitability.”
Emerson joined IDEXX in November 2015, leading the finance organization for the companion animal group business since then. In March 2020, he also assumed responsibility for the corporate finance function, including investor relations, financial planning and analysis, accounting, tax and treasury.
Before joining IDEXX, Emerson worked as vice president and finance and business unit controller at Medtronic (NYSE: MDT), an American-Irish medical device company headquartered in Dublin, Ireland.
He joined Medtronic through its acquisition of Covidien, an Ireland-based health technology and medical supplies provider. There he held various finance positions including controller for the advanced surgical technologies business unit.
Emerson earned a bachelor’s degree in accounting and business management from Northeastern University.
Along with Thursday's announcement of the CFO transition, IDEXX reaffirmed its 2024 full-year financial guidance issued on Oct. 31.
In its most recent quarterly report, IDEXX posted an increase in earnings and revenue but cut its full-year earnings and revenue outlook.
As of Thursday's close on Wall Street, IDEXX shares have a market value of around $34.3 billion. The stock is trading 12.5% lower than a year ago.
Most Recent
Most Recent
0 Comments